Table 2.

Plasma AVP concentration, and urinary AVP and cAMP excretion before (–2–0 h) and after oral administration of 1, 5, or 10 mgasimadoline as compared with placebo in each group of eight healthy subjects in the absence (0–2 h) and presence of 2.5% saline infusion (2–4 h).*P < 0.05.

Parameter	Collection interval	Placebo	1 mg asimadoline	Placebo	5 mg asimadoline	Placebo	10 mg asimadoline
Plasma AVP concentration
(fmol ml−1)
	−2–0 h	2.3 ± 1.4	2.0 ± 1.0	2.2 ± 0.6	2.0 ± 0.3	3.6 ± 3.4	3.0 ± 1.4
	0–2 h	2.9 ± 1.0	1.8 ± 0.6	2.6 ± 1.9	1.9 ± 1.0	2.9 ± 2.2	3.5 ± 2.3
	2–4 h (2.5% NaCl i.v.)	5.4 ± 1.6	5.1 ± 1.4	4.2 ± 1.4	4.1 ± 2.3	5.7 ± 2.3	4.2 ± 1.9*
Urinary AVP excretion
(fmol min−1)
	−2–0 h	30 ± 17	29 ± 22	22 ± 13	26 ± 9	40 ± 27	22 ± 13
	0–2 h	30 ± 15	28 ± 13	22 ± 10	21 ± 10	46 ± 23	25 ± 16*
	2–4 h (2.5% NaCl i.v.)	316 ± 121	278 ± 59	220 ± 89	244 ± 70	410 ± 206	181 ± 125*
Urinary cAMP excretion
(pmol min−1)
	−2–0 h	2.7 ± 0.8	2.4 ± 0.5	2.5 ± 0.5	2.3 ± 0.3	2.8 ± 0.8	2.4 ± 0.3
	0–2 h	2.8 ± 0.8	2.9 ± 0.3	2.7 ± 0.3	2.8 ± 0.8	2.8 ± 0.3	2.6 ± 0.3
	2–4 h (2.5% NaCl i.v.)	4.7 ± 1.1	4.7 ± 0.8	4.0 ± 1.1	3.9 ± 1.1	3.4 ± 0.5	3.6 ± 0.5